Opdivo (nivolumab)

pCPA File Number: 22041
Negotiation Status:
Concluded with an LOI
Indication(s):
Indicated as monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CDA-AMC Project Number:
PC0272
pCPA Engagement Letter Issued:
Negotiation Process Concluded: